NCT00158964已完成2 期
EASYTRAK® 4 STEERABLE LV Lead Clinical Investigation
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 110
- 试验地点
- 2
- 主要终点
- Lead-related complication free-rate at 3-months.
研究概览
简要总结
The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the EASYTRAK 4 STEERABLE LV lead.
详细描述
This is a prospective, multi-center clinical study is to evaluate the safety and effectiveness of the EASYTRAK 4 STEERABLE LV lead.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must receive a commercially available Guidant CRT-P or CRT-D device
- •Creatinine < 2.5 mg/dL obtained no more than two weeks prior to enrollment
- •Age 18 or above, or of legal age to give informed consent specific to state and national law
- •Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigation center and at the intervals defined by this protocol
- •Geographically stable residents who are available for follow-up
排除标准
- •Have a known hypersensitivity to a 1.0 mg (0.5 mg per electrode) nominal dose of dexamethasone acetate
- •Have or had previous cardiac resynchronization therapy, a coronary venous pace/sense lead or attempted LV lead placement
- •Have pre-existing cardioversion/defibrillation leads or right ventricular pacing leads other than those specified in the investigational plan (unless the investigator intends to replace them with permitted cardioversion/defibrillation leads)
- •Currently requiring dialysis
- •Have had a myocardial infarct, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment
- •Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis)
- •Documented life expectancy of less than six months or expected to undergo heart transplant within the next six months
- •Enrolled or participating in any concurrent study, including drug investigations, without Guidant written approval, that may confound the results of this study
- •Have a pre-existing unipolar pacemaker that will not be explanted/abandoned
- •Have a mechanical tricuspid heart valve
- •Women who are pregnant or plan to become pregnant Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment.
结局指标
主要结局
Lead-related complication free-rate at 3-months.
Chronic mean pacing thresholds at 3-months.
次要结局
- Chronic Mean pacing impedances at 3-months
- Chronic Mean R-wave amplitudes at 3-months
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
EASYTRAK 3 Downsize LeadHeart FailureNCT00384722Boston Scientific Corporation70
已完成
不适用
The EASYTRAK EPI Clinical InvestigationBradycardiaCongestive Heart FailureNCT00158925Boston Scientific Corporation100
已完成
2 期
Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense LeadCongestive Heart FailureNCT00158938Boston Scientific Corporation115
已完成
4 期
A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA StudySjögren SyndromeHyposalivationHead and Neck CancerXerostomiaNCT02049112Unither Pharmaceuticals, France210
进行中（未招募）
4 期
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in IndiaAnemiaNCT05891249Bristol-Myers Squibb85